Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 3/20 | 0.65 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.65 |
| ▸ | MAOB | P27338 | 5/20 | 0.55 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.54 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.54 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | FNTA | P49354 | 1/20 | 0.47 |
| ▸ | FNTB | P49356 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | GYS1 | P13807 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3500758 | 0.81 | MAOB (0.63) | LPAR1LPAR5MAOBPARP15PARP14 | |
| SCHEMBL5425774 | 0.79 | LPAR1 (0.59) | LPAR1LPAR5MAOBPARP15PARP14 | |
| SCHEMBL16507246 | 0.79 | LPAR1 (1.00) | LPAR1LPAR5MAOBPARP15PARP14 | |
| SCHEMBL28570332 | 0.79 | FFAR1 (0.71) | MAOB | |
| Hydrochloric Acid SCHEMBL7865895 | 0.78 | LPAR1 (0.52) | LPAR1LPAR5MAOBPARP15PARP14 | |
| SCHEMBL5428157 | 0.77 | LPAR1 (0.59) | LPAR1LPAR5MAOBPARP15PARP14 | |
| SCHEMBL16507526 | 0.76 | LPAR1 (0.80) | LPAR1LPAR5MAOBPARP15PARP14 | |
| SCHEMBL186172 | 0.75 | MEP1B (0.50) | KEAP1PPARGPPARAALDH1A1 | |
| SCHEMBL1444784 | 0.75 | MAOB (0.75) | LPAR1LPAR5MAOBPARP15PARP14 | |
| SCHEMBL2937570 | 0.74 | MAOB (0.71) | LPAR1LPAR5MAOBPARP15PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005049589-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA, DIABETES, OBESITY AND SIMILAR DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2005-06-02 | — | — | WO | claimed |
| US-20070275956-A1 | Novel Heterocyclic Compounds | CADILA HEALTHCARE LIMITED (IN) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275956-A1 | Novel Heterocyclic Compounds | CYP46A1, DHCR7, NPC1L1 | LPAR1 1252/4885LPAR5 1037/4885MAOB 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.